Aurobindo Pharma launches generic Advair Diskus in US
Aurobindo Pharma's subsidiary Lannett Company LLC has launched the generic equivalent of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in the US market, the company announced on Monday.
The product, manufactured by GSK plc, is available in 100/50 mcg and 250/50 mcg strengths. Advair Diskus is a combination therapy indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
"This launch marks the first product from our inhalation pipeline to be commercialized in the US, reflecting our continued focus on expanding our portfolio of complex and differentiated inhalation products," Aurobindo Pharma said in an exchange filing. The company also stated that Lannett Company LLC is a wholly owned subsidiary of Aurobindo Pharma USA, Inc.
Following the announcement, Aurobindo Pharma shares rose over 3% in trade on Monday, August 31. The stock hit an intra-day high of Rs 1,703 apiece on the NSE, up 3.5%. At 1:50 PM, the share price was Rs 1,682.90, up 2.29% from its previous close of Rs 1,645.30. During the session, nearly 14 lakh equity shares, valued at around Rs 235 crore, exchanged hands on the BSE and NSE.
Aurobindo Pharma shares have delivered a return of 41.16% year-to-date in 2026 and gained 63.83% over the past year. At the current market price, the company commands a market capitalisation of Rs 96,721.02 crore on the NSE.
Aurobindo Pharma, headquartered in Hyderabad, India, is an integrated global pharmaceutical company operating in more than 150 countries. It has over 30 manufacturing and packaging facilities approved by leading regulatory agencies, including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC and Brazil ANVISA. Its product portfolio spans seven major therapeutic and product areas, including CNS, anti-retroviral, CVS, antibiotics, gastroenterology, anti-diabetics and anti-allergic products.